Navigation Links
Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
Date:2/19/2008

The Next Step Involves Combining the 350+ Targeted Drugs on the Market and in Clinical Development with Each Other to Block Key Pathways to Combat Drug Resistance, Enhance Anticancer Effects, and Expand the Markets for

Targeted Drugs

LAKE FOREST, Calif., Feb. 19 /PRNewswire/ -- Identification of novel cancer-related targets and pathways is redefining our understanding of the nature of malignancy. Molecular profiling is prompting new, more detailed classifications of malignancy enabling the development of specific/personalized cancer therapies. Standard classifications involving gross pathologic hallmarks such as stage and grade are now being further augmented by data detailing the overexpression of oncogenes, silencing of tumor suppressors and presence of mutant forms of relevant markers. In each of these cases novel targeted agents and various combination strategies are being investigated based on the specific molecular profiles of cancer subtypes.

Molecular Profiling Improves Classification and Guides Treatment

In breast cancer, for example, classification has been extended to include metastatic sites (bone, brain), expression of HEr2, and hormone receptor status. A recently introduced classification is triple negative (Er-, Pgr- and HEr2-) breast cancer, also known as basal-cell cancer. Other classifications include inflammatory breast cancer and ductal carcinoma in situ. Different treatment strategies are in development for each of these tumor types. Similarly, most other malignancies are also undergoing reclassification based on specific molecular profiles. Elucidation of the role of Kras in the success or failure of EGFr inhibition in the treatment of colorectal cancer exemplifies the recent remarkable achievements that have been made based on molecular profiling. Authoritative cancer agencies are taking notice. The National Comprehensive Cancer Network (NCCN) has begun to incorporate diagnostic, prognostic and pharmacogenomic evaluations in their updated treatment guidelines.

Targeted Agents in Combination are Entering Clinical Trials

The validated association of aggressive disease and the overexpression of HEr2 in any type or stage of breast cancer have created a $4 billion global market for trastuzumab (Herceptin; Genentech) in 2007. Still, nearly 50% of HEr2-positive patients do not respond to trastuzumab, and survival benefits are transient, often lasting under a year. Furthermore, side effects remain a significant problem. Despite these limitations, trastuzumab is the standard of treatment for both early stage and advanced or metastatic disease and is undergoing clinical trials in combination with numerous approved or novel anticancer agents.

Hundreds of clinical trials are underway combining approved targeted therapeutics with every applicable cytotoxic(s) with the goal of achieving incremental benefits. The greater opportunity, however, may lie in combining targeted therapeutics that address different points in one pathway or interacting pathways involved in angiogenesis, metastasis, drug resistance, and tumor growth and survival. This approach has entered the clinic; recently initiated trials are testing combinations of approved targeted therapeutics with each other. The full impact of combining target agents, however, will not be measured until approved and novel agents are combined in hundreds of different combinations for the treatment of hundreds of specific cancer indications.

Future Oncology Series Details ErbB Pathway-targeted Therapeutics

To date, ErbB pathway abnormalities, which occur in a large number of malignancies, have been the most extensively targeted. Currently, there are 7 approved agents targeting this pathway and over 620 clinical trials are ongoing with these agents in various combinations, mostly with cytotoxic agents but also with each other and with selected novel agents under clinical development. In addition to the over 56 ErbB-targeted agents in development (35 in current clinical trials), numerous molecular markers/pathways are being recognized as contributing to the success or failure of the ErbB pathway inhibitors. A series of reports (http://www.newmedinc.com/futonc/sample.pdf) on currently approved therapeutics as well as those in development targeting the ErbB pathway, including EGFr and HEr2 inhibitors, published by Future Oncology (http://www.newmedinc.com), highlights the contribution of molecular profiling in the characterization of cancer and its treatment.

New Medicine's Oncology KnowledgeBASE (nm|OK) is a Complete Knowledge Environment in Drug Development in Cancer

Unlike standard drug databases, nm|OK residing at http://www.nmok.net, is designed to specifically provide a fully realized environment reflecting every aspect of drug development in oncology. nm|OK is an edited, inclusive analysis of all aspects of oncology drug development worldwide, including technologies, targets, companies, business affiliations, medical and clinical developments, protocols and results of thousands of clinical trials, and global markets, among others. Currently, nm|OK profiles over 2,000 anticancer agents/technologies in current development (over 4,000 drugs overall) or on the market, more than 1,200 targets implicated in malignancy, and more than 2,000 companies developing/marketing products in the oncology sector. Protocols, interim and final results are presented for thousands of trials, searchable by both novel and approved agents in monotherapy or combination therapy regiments. In addition, nm|OK describes hundreds of diagnostic, prognostic, and theragnostic methodologies and products as they relate to treatment candidate selection, evaluation of the results of clinical trials, and early and accurate detection of disease.

Contact us for an online demonstration of nm|OK.

Contact: Katie Siafaca

New Medicine, Inc.

Tel: (949) 830-0448; Fax: (949) 830-0887

E-mail: info@newmedinc.com

http://www.newmedinc.com/

http://nmok.net/

http://nmok.net/oksite/samprecords.html


'/>"/>
SOURCE New Medicine, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
2. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
3. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
4. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
5. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
6. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
7. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
8. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
9. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
10. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... , ... TherapySites, the leading website and online ... Counseling Association. This new relationship allows TherapySites to continue to extend their ... benefits and promotional offers. , "TCA is extremely excited about this new partnership, ...
(Date:6/26/2016)... ... , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center ... Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This annual ... the world’s leading providers of cereal and other breakfast foods. Its residents often refer ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
Breaking Medicine News(10 mins):